CA2255748A1 - Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders - Google Patents
Uridine-comprising therapeutic active agent for treatment of neurodegenerative disordersInfo
- Publication number
- CA2255748A1 CA2255748A1 CA002255748A CA2255748A CA2255748A1 CA 2255748 A1 CA2255748 A1 CA 2255748A1 CA 002255748 A CA002255748 A CA 002255748A CA 2255748 A CA2255748 A CA 2255748A CA 2255748 A1 CA2255748 A1 CA 2255748A1
- Authority
- CA
- Canada
- Prior art keywords
- uridine
- treatment
- neuron
- ngf
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 abstract 8
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 abstract 4
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 abstract 4
- 229940045145 uridine Drugs 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 3
- 210000002569 neuron Anatomy 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 230000032683 aging Effects 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000002155 anti-virotic effect Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000004748 cultured cell Anatomy 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 239000007952 growth promoter Substances 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000004693 neuron damage Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000001228 trophic effect Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Uridine is a therapeutic agent active as a growth promoter for treatment of neuron degenerative diseases deriving from pathological ageing or selective destruction, in particular uridine shows the same biological effects of NGF, when added at low doses to the culture medium, so that uridine may replace NGF
as therapeutic agent in neural diseases and it may be also associated to other growth factors that allow neuron's differentiation, or with anti-cancer and anti-virus drugs that cause neuron damage. In addition uridine shows imporant trophic properties on various types of cultured cells, stimulating cell reproduction when used at rather high dose levels.
as therapeutic agent in neural diseases and it may be also associated to other growth factors that allow neuron's differentiation, or with anti-cancer and anti-virus drugs that cause neuron damage. In addition uridine shows imporant trophic properties on various types of cultured cells, stimulating cell reproduction when used at rather high dose levels.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM96A000364 | 1996-05-28 | ||
| IT96RM000364A IT1290781B1 (en) | 1996-05-28 | 1996-05-28 | ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES. |
| PCT/IT1997/000117 WO1997045127A1 (en) | 1996-05-28 | 1997-05-23 | Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2255748A1 true CA2255748A1 (en) | 1997-12-04 |
| CA2255748C CA2255748C (en) | 2002-12-03 |
Family
ID=11404245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002255748A Expired - Fee Related CA2255748C (en) | 1996-05-28 | 1997-05-23 | Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP3725172B2 (en) |
| BR (1) | BR9709379A (en) |
| CA (1) | CA2255748C (en) |
| HU (1) | HUP0000124A3 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005112635A2 (en) * | 2004-05-13 | 2005-12-01 | Massachusetts Institute Of Technology | Uridine effects on dopamine release |
| JP2008513453A (en) * | 2004-09-15 | 2008-05-01 | マサチューセッツ インスティテュート オブ テクノロジー | Compositions containing uridine and methods of use thereof |
| WO2007060886A1 (en) * | 2005-11-24 | 2007-05-31 | National University Corporation Hokkaido University | Therapeutic agent for neurodegenerative disease |
| WO2023167252A1 (en) * | 2022-03-01 | 2023-09-07 | ヤマサ醤油株式会社 | Bdnf production promoter |
-
1997
- 1997-05-23 JP JP54197097A patent/JP3725172B2/en not_active Expired - Fee Related
- 1997-05-23 CA CA002255748A patent/CA2255748C/en not_active Expired - Fee Related
- 1997-05-23 HU HU0000124A patent/HUP0000124A3/en unknown
- 1997-05-23 BR BR9709379-3A patent/BR9709379A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0000124A2 (en) | 2000-05-28 |
| CA2255748C (en) | 2002-12-03 |
| BR9709379A (en) | 2000-01-11 |
| JP2000503668A (en) | 2000-03-28 |
| JP3725172B2 (en) | 2005-12-07 |
| HUP0000124A3 (en) | 2000-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DeLorenzo | Calcium-dependent phosphorylation of specific synaptosomal fraction proteins: possible role of phosphoproteins in mediating neurotransmitter release | |
| PT923293E (en) | TREATMENT OF DIARRHEA | |
| IL85746A0 (en) | Preparation of t cells and t cell membrane for use in autoimmune diseases | |
| AU1916995A (en) | 4-amino derivatives of mycophenolic acid with immunosuppressant activity | |
| HUP9800028A2 (en) | Multiple-tumor aberrant growth genes | |
| CA2265464A1 (en) | Therapy for .alpha.-galactosidase a deficiency | |
| AU3667293A (en) | Methods and compositions of a polymer (poloxamer) for cell repair | |
| RU95115822A (en) | Biological factors and neuronal stem cells | |
| CA2168029A1 (en) | Prosaposin and cytokine-derived peptides as therapeutic agents | |
| AU682140B2 (en) | Multidrug resistance gene | |
| DE69334224D1 (en) | LYMPHOTOXIN-BETA, LYMPHOTOXIN-BETA COMPLEXES, PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC USES THEREOF | |
| EP0352581A3 (en) | Ethylene diaminmonoamide derivatives | |
| CA2144514A1 (en) | Morphogen-induced liver regeneration | |
| WO1999062940A3 (en) | Methods of altering cardiac cell phenotype | |
| DE69637825D1 (en) | S-NITROSOTHIOL-ENRICHED ERYTHROCYTES AND THEIR USE | |
| CA2199832A1 (en) | Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease | |
| IL123642A (en) | Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration | |
| Wachtel | Comparison of anticholinesterases and their effects on acetylcholine-activated ion channels | |
| CA2255748A1 (en) | Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders | |
| CA2194485A1 (en) | Endothelial lining effects and treatment of vasospastic disorders | |
| WO1991001744A3 (en) | Uses of interleukin-4 and method for purifying it | |
| AU2394388A (en) | Treatment of diseases with paf-acether-antagonists and procedure for determining their efficacy | |
| CA2380943A1 (en) | Mechanically elongated neuronal cells and methods for producing and using these cells | |
| CA2235951A1 (en) | Novel uses of mammalian ctla-8 and related reagents | |
| ATE108331T1 (en) | USE OF TNF IN THE MANUFACTURE OF A MEDICATION FOR THE TREATMENT OF PSORIASIS. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |